You are here

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Last updated on December 6, 2018

FOR MORE INFORMATION
Study Location
Harbor-UCLA Medical Center
Torrance, California, 90502 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Serious Bacterial Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Subject must be ≥18 years of age.

2. Evidence of a personally signed and dated informed consent document indicating that
the subject or a legally acceptable representative has been informed of all pertinent
aspects of the study.

3. Subjects must have a confirmed diagnosis of serious bacterial infection, specifically
cIAI, HAP/VAP, cUTI, or BSI requiring administration of IV antibacterial therapy.

4. Subjects must have an MBL- positive Gram- negative bacteria (an Enterobacteriaceae
and/or Stenotrophomonas maltophilia for which the imipenem or meropenem MIC is ≥ 4
µg/mL), that was isolated from an appropriate specimen obtained within 5 days prior to
screening.

5. Female subject of childbearing potential must have a negative serum or urine pregnancy
test, with sensitivity of at least 25 mIU/mL.

6. Subjects who have received appropriate prior systemic antibiotic[s] for a carbapenem
non-susceptible pathogen must meet the following criteria (Note: antibiotic[s] is
considered appropriate if microbiological susceptibility test results show that all
carbapenem non-susceptible pathogens are susceptible to the systemic antibiotic[s]
received):

1. Worsening or lack of improvement of objective symptoms or signs of infection
after at least 48 hours of antibacterial therapy Note: Symptomatic subjects (see
inclusion criteria 3 and 4) with an isolated causative pathogen that was not
susceptible to the prior systemic therapy are eligible for this trial.

7. Subject must be willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.

Additional Inclusion Criteria- cIAI Subjects

1. Subject must have a specimen obtained from an abdominal source during a surgical
intervention within 5 days prior to screening from which a study qualifying pathogen
was isolated upon culture. Surgical intervention includes open laparotomy,
percutaneous drainage of an abscess, or laparoscopic surgery.

2. The subject has at least 1 of the following diagnosed during the surgical
intervention:

- Cholecystitis with gangrenous rupture or perforation or progression of the
infection beyond the gallbladder wall;

- Diverticular disease with perforation or abscess;

- Appendiceal perforation or peri-appendiceal abscess;

- Acute gastric or duodenal perforations, only if operated on >24 hours after
diagnosis;

- Traumatic perforation of the intestines, only if operated on >12 hours after
diagnosis;

- Other secondary peritonitis (not primary/ spontaneous bacterial peritonitis
associated with cirrhosis or chronic ascites);

- Intra abdominal abscess (including of the liver and spleen provided that there is
extension beyond the organ with evidence of intra peritoneal involvement).

3. Subject has at least 1 of the following signs / symptoms from each of the following 2
groups:

- Group A: Evidence of systemic inflammatory response:

- Documented fever (defined as body temperature ≥38°C) or hypothermia (with a
rectal core body temperature ≤35°C);

- Elevated white blood cells (WBC) (>12000 cells/µL);

- Systolic blood pressure (SBP) or a SBP decrease of >40 mmHg;

- Increased heart rate ( >90 beats per minute [bpm]) and respiratory rate (>20
breaths/min);

- Hypoxemia (defined as oxygen [O2] saturation

- Altered mental status.

- Group B: Physical findings consistent with intra abdominal infection, such as:

- Abdominal pain and/or tenderness, with or without rebound;

- Localized or diffuse abdominal wall rigidity;

- Abdominal mass.

Additional Inclusion Criteria - HAP/VAP Subjects

1. Onset of symptoms >48 hours after admission or inpatient care facility (for which the duration of admission was >3 days).

2. New or worsening infiltrate on chest X- ray (or computerized tomography [CT]- scan)
obtained within 48 hours prior to randomization.

3. At least 1 of the following:

• Documented fever (temperature ≥38°C) or hypothermia (rectal/core temperature ≤35°C);

• WBC ≥10,000 cells/mm3, leukopenia with total WBC ≤4500 cells/mm3, or >15% immature
neutrophils (bands) noted on peripheral blood smear.

4. At least 2 of the following:

• A new cough (or worsening of cough at Baseline);

• Production of purulent sputum or purulent endotracheal secretions;

• Auscultatory finding consistent with pneumonia/pulmonary consolidation (eg, rales,
rhonchi, bronchial breath sounds, dullness on percussion, egophony);

• Dyspnea, tachypnea, or hypoxemia (O2 saturation [pO2]

• Need for acute changes in the ventilator support status/system to enhance
oxygenation, as determined by worsening oxygenation (arterial blood gas [ABG] or pO2
in arterial blood [PaO2]/fraction of inspired O2 [FiO2]) or needed changes in the
amount of positive end expiratory pressure.

5. Subjects must have a respiratory specimen obtained within 5 days prior to screening
for Gram stain and culture from which a study qualifying pathogen was isolated upon
culture. This includes culture of either an expectorated sputum or a specimen of
respiratory secretions obtained by endotracheal aspiration in intubated subjects, or
by bronchoscopy with bronchoalveolar lavage (BAL), mini BAL or protected specimen
brush (PSB) sampling.

Additional Inclusion Criteria - cUTI Subjects

1. Subject had urine within 5 days prior to screening that cultured positive; containing
≥10^5 colony forming unit (CFU)/mL of at least 1 carbapenem non susceptible, MBL
positive Gram negative bacteria, ie, the isolate from the study qualifying culture.

2. Subject had pyuria in the 5 days prior to screening as determined by a midstream clean
catch or catheterized urine specimen with ≥10 white blood cells (WBCs) per HighPower
Field (HPF) on standard examination of urine sediment or ≥10 WBCs/mm3 in unspun urine.

3. Subject demonstrates either acute pyelonephritis or complicated lower UTI without
pyelonephritis as defined by the following criteria:

a. Acute pyelonephritis indicated by flank pain (which must have onset or worsened
within 7 days of enrollment) or costovertebral angle tenderness on examination and at
least 1 of the following: i) Fever, defined as body temperature ≥38°C (with or without
patient symptoms of rigor, chills, or warmth); ii) Nausea and/or vomiting. OR b.
Complicated lower UTI, as indicated by qualifying symptoms plus at least 1
complicating factor as follows: i) Qualifying symptoms: subject must have at least 2
of the following symptoms with at least 1 symptom from Group A:

• Group A symptoms include dysuria, urgency, frequency, and or suprapubic pain;

- Group B symptoms include fever (defined as body temperature ≥38°C with or without
patient symptoms of rigor, chills, warmth), nausea, and/or vomiting.

ii) Complicating factors: subject must have at least 1 of the following complicating
factors:

• Documented history of urinary retention (male subjects);

• Obstructive uropathy that is scheduled to be medically or surgically relieved during
study therapy and before the EOT;

- Functional or anatomical abnormality of the urogenital tract, including anatomic
malformations or neurogenic bladder, or with a postvoid residual urine volume of
at least 100 mL;

- Use of intermittent bladder catheterization or presence of an indwelling bladder
catheter for at least 48 hours;

- Urogenital procedure (such as cystoscopy or urogenital surgery) within the 7 days
prior to obtainment of the specimen used for the study qualifying culture.

Additional Inclusion Criteria - BSI Subjects

1. Subject has a confirmed diagnosis of primary BSI or catheter related BSI (CR- BSI).

2. Consecutive positive duplicate blood cultures (n=2) within 5 days prior to screening
indicating presence of a carbapenem non- susceptible, MBL-producing Gram- negative
bacteria. Subjects with polymicrobial blood infections may be included in the study.

3. Signs and symptoms of systemic infection characterised by at least one of the
following:

a. Chills, rigors, or fever (temperature of ≥38.0°C or ≥100.4°F); b. Elevated white
blood cell count (≥10,000/mm3) or left shift (>15% immature polymorphonuclear
leukocytes (PMNs)).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Evaluation (APACHE) II score >30.

2. Subjects unlikely to respond to up to 14 days of study treatment. 3. History of serious
allergic reaction (anaphylaxis, angioedema, bronchospasm, hypersensitivity) to any systemic
antibacterial allowed per protocol.

4. Subject has previously been treated with ATM-AVI Subject with known Clostridium
difficile associated diarrhea. 5. Subjects with perinephric infection. 6. Colonization with
an MBL-producing Gram-negative bacteria without signs or symptoms.

7. Estimated CrCL ?15 mL/min or anticipated requirement for dialysis during the study.

8. Hepatic disease as indicated by ALT or AST >3 x ULN at Screening. Exception: AST and/or
ALT up to 5 x ULN if these elevations are acute and directly related to the infectious
process.

9. Bilirubin >2 x ULN, unless related to the acute infection or due to known Gilbert's
disease.

10. Alkaline phosphatase (ALP) >3 x ULN. Exception: up to and related to the infectious process.

11. Absolute neutrophil count

Additional Exclusion Criteria - cIAI Subjects

1. Subject has infections limited to the hollow viscous, such as simple cholecystitis,
gangrenous cholecystitis without rupture, and simple appendicitis, or has acute suppurative
cholangitis, infected necrotizing pancreatitis, or pancreatic abscess.

2. Subject has abdominal wall abscess or small bowel obstruction without perforation or
ischemic bowel without perforation.

3. Subject has a cIAI managed by staged abdominal repair (STAR), or "open abdomen"
technique, or marsupialization. This criterion is intended to exclude subjects in whom the
abdomen is left open, particularly those for whom re operation is planned.

4. Subject who has prior liver, pancreas or small bowel transplant.

Additional Exclusion Criteria - HAP/VAP Subjects 1. APACHE II score lung abscess, pleural empyema, or post obstructive pneumonia. 3. Subject is a recipient of
a lung or heart transplant. 4. Subjects with myasthenia gravis.

Additional exclusion criteria - cUTI Subjects

1. Subjects with suspected or confirmed complete obstruction of any portion of the
urinary tract, perinephric or intrarenal abscess, or prostatitis, or history of any
illness that, in the opinion of the investigator, may confound the results of the
study or pose additional risk in administering the study therapy to the subject.

2. Subjects with renal transplantation.

3. Subjects with a permanent urinary diversion (eg, with ileal loops, cutaneous
ureterostomy or vesicoureteral reflux).

4. Subjects who are likely to receive ongoing antibacterial drug prophylaxis after
treatment of cUTI (eg, subjects with vesico-ureteric reflux).

5. Any recent history of trauma to the pelvis or urinary tract.

6. Subjects with uncomplicated urinary tract infections (generally female subjects with
urinary frequency, urgency, or pain or discomfort without systemic symptoms or signs
of infection).

Additional exclusion criteria - BSI Subjects

1. Subject has a prosthetic cardiac valve or synthetic endovascular graft. 2. Subject has a
suspected or documented medical condition with well-defined requirement for prolonged
antibiotic treatment (eg, infectious endocarditis, osteomyelitis/septic arthritis,
undrainable/undrained abscess, unremoveable/unremoved prosthetic associated infection).

NCT03580044
Pfizer
Not yet recruiting
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

HIV Infections
NCT00002266
All Genders
18+
Years
Tucson, Arizona
Neisseria Meningitidis (Bacterial Meningitis), Invasive Pneumococcal Disease (IPD)
NCT00617760
All Genders
1+
Years
Multiple Sites
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
A Prospective, Randomized, Open-label, Comparative Study To Assess The Efficacy, Safety And Tolerability Of Aztreonam- Avibactam (ATM-AVI) And Best Available Therapy For The Treatment Of Serious Infections Due To Multi-drug Resistant Gram-Negative Bacteria Producing Metallo -?- Lactamase (MBL)
Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP), complicated urinary tract infections (cUTI), or bloodstream infections (BSI) due to metallo-?-lactamase (MBL)- producing Gram-negative bacteria.

This is a prospective, randomized, multicenter, open-label, parallel group, comparative study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP), complicated urinary tract infections (cUTI), or bloodstream infections (BSI) due to metallo-?-lactamase (MBL)- producing Gram-negative bacteria.

The study will randomize approximately 60 subjects in a 2:1 randomization scheme (ATM-AVI: BAT) with infections due to MBL-producing Gram-negative bacteria. Molecular testing at the central microbiology laboratory will be performed to confirm the MBL status of the organism upon study completion or at pre-designated intervals.

The study will consist of a Screening Visit (Visit 1), a Baseline visit (Visit 2) on Day 1 of the study treatment, ongoing treatment visits (Visits 3 to 15) from Day 2 to Day 14, an End of Treatment (EOT) visit (Visit 16) within 24 hours after the last infusion, a Test of Cure (TOC) visit (Visit 17) on Day 28 (±3 days) and a Late Follow Up (LFU) visit (Visit 18) on Day 45 (±3 days).

Subjects will be stratified at randomization based on infection type (cIAI, HAP/VAP, cUTI or BSI). The number of subjects with cUTI will be no more than approximately 75% of the study population.

After obtaining written informed consent and confirming eligibility, subjects will be randomized in a 2:1 ratio to the ATM AVI treatment arm or the BAT treatment arm according to a central randomization schedule (approximately 40 (ATM AVI) and approximately 20 (BAT) subjects per group).

The duration of treatment is 5 to 14 days for cIAI, cUTI and BSI and 7 to 14 days for HAP/VAP. Each subject is expected to complete the study, including the LFU visit. The precise duration of treatment will be determined by the investigator based on the subject's severity of infection and subsequent response to treatment.

For subjects randomized to ATM AVI treatment arm, sparse blood samples will be collected for population pharmacokinetic (PK) assessments and PK/pharmacodynamic (PD) relationships will be evaluated in subjects where plasma samples and microbiological response data have been collected.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Serious Bacterial Infection
  • Combination Product: ATM-AVI

    ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours.

    Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.

    Other Name: Aztreonam- Avibactam
  • Drug: BAT
    The comparator treatments in this study are to be the best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT for each subject must be recorded prior to randomization. Acceptable BAT may include but not limit to the following Aminoglycoside; Colistin (or polymixin B if colistin not available/accessible); Fosfomycin; Meropenem; Tigecycline. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
    Other Name: Best Available Therapy
  • Experimental: ATM- AVI
    Aztreonam- Avibactam (ATM-AVI) Active Treatment Arm
    Intervention: Combination Product: ATM-AVI
  • Active Comparator: BAT
    Best Available Therapy (BAT) Comparator Treatment Arm
    Intervention: Drug: BAT
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
60
Same as current
June 28, 2020
June 28, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria All Subjects

  1. Subject must be ?18 years of age.
  2. Evidence of a personally signed and dated informed consent document indicating that the subject or a legally acceptable representative has been informed of all pertinent aspects of the study.
  3. Subjects must have a confirmed diagnosis of serious bacterial infection, specifically cIAI, HAP/VAP, cUTI, or BSI requiring administration of IV antibacterial therapy.
  4. Subjects must have an MBL- positive Gram- negative bacteria (an Enterobacteriaceae and/or Stenotrophomonas maltophilia for which the imipenem or meropenem MIC is ? 4 µg/mL), that was isolated from an appropriate culture obtained within 5 days prior to study entry.
  5. Female subject of childbearing potential must have a negative serum or urine pregnancy test, with sensitivity of at least 25 mIU/mL.
  6. Subjects who have received appropriate prior systemic antibiotic[s] for a carbapenem non-susceptible pathogen must meet the following criteria (Note: antibiotic[s] is considered appropriate if microbiological susceptibility test results show that all carbapenem non-susceptible pathogens are susceptible to the systemic antibiotic[s] received):

    1. Worsening or lack of improvement of objective symptoms or signs of infection after at least 48 hours of antibacterial therapy Note: Symptomatic subjects (see inclusion criteria 3 and 4) with an isolated causative pathogen that was not susceptible to the prior systemic therapy received or who received no prior systemic therapy are eligible for this trial.
  7. Subject must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Additional Inclusion Criteria- cIAI Subjects

  1. Subject must have a study qualifying specimen obtained from an abdominal source during a surgical intervention within the 5 days prior to study entry. Surgical intervention includes open laparotomy, percutaneous drainage of an abscess, or laparoscopic surgery.
  2. The subject has at least 1 of the following diagnosed during the surgical intervention:

    • Cholecystitis with gangrenous rupture or perforation or progression of the infection beyond the gallbladder wall;
    • Diverticular disease with perforation or abscess;
    • Appendiceal perforation or peri-appendiceal abscess;
    • Acute gastric or duodenal perforations, only if operated on >24 hours after diagnosis;
    • Traumatic perforation of the intestines, only if operated on >12 hours after diagnosis;
    • Other secondary peritonitis (not primary/ spontaneous bacterial peritonitis associated with cirrhosis or chronic ascites);
    • Intra abdominal abscess (including of the liver and spleen provided that there is extension beyond the organ with evidence of intra peritoneal involvement).
  3. Subject has at least 1 of the following signs / symptoms from each of the following 2 groups:

    • Group A: Evidence of systemic inflammatory response:
    • Documented fever (defined as body temperature ?38°C) or hypothermia (with a rectal core body temperature ?35°C);
    • Elevated white blood cells (WBC) (>12000 cells/µL);
    • Systolic blood pressure (SBP) <90 mmHg or mean arterial pressure (MAP) <70 mmHg, or a SBP decrease of >40 mmHg;
    • Increased heart rate ( >90 beats per minute [bpm]) and respiratory rate (>20 breaths/min);
    • Hypoxemia (defined as oxygen [O2] saturation <95% by pulse oximetry);
    • Altered mental status.
    • Group B: Physical findings consistent with intra abdominal infection, such as:
    • Abdominal pain and/or tenderness, with or without rebound;
    • Localized or diffuse abdominal wall rigidity;
    • Abdominal mass.

Additional Inclusion Criteria - HAP/VAP Subjects

  1. Onset of symptoms >48 hours after admission or <7 days after discharge from an inpatient care facility (for which the duration of admission was >3 days).
  2. New or worsening infiltrate on chest X- ray (or computerized tomography [CT]- scan) obtained within 48 hours prior to randomization.
  3. At least 1 of the following:

    ? Documented fever (temperature ?38°C) or hypothermia (rectal/core temperature ?35°C);

    ? WBC ?10,000 cells/mm3, leukopenia with total WBC ?4500 cells/mm3, or >15% immature neutrophils (bands) noted on peripheral blood smear.

  4. At least 2 of the following:

    ? A new cough (or worsening of cough at Baseline);

    ? Production of purulent sputum or purulent endotracheal secretions;

    ? Auscultatory finding consistent with pneumonia/pulmonary consolidation (eg, rales, rhonchi, bronchial breath sounds, dullness on percussion, egophony);

    ? Dyspnea, tachypnea, or hypoxemia (O2 saturation <90% or partial pressure of O2 [pO2]<60 mmHg while breathing room air);

    ? Need for acute changes in the ventilator support status/system to enhance oxygenation, as determined by worsening oxygenation (arterial blood gas [ABG] or pO2 in arterial blood [PaO2]/fraction of inspired O2 [FiO2]) or needed changes in the amount of positive end expiratory pressure.

  5. Subjects must have a study qualifying respiratory specimen obtained for Gram- stain and culture within the 5 days prior to study entry. This includes a culture either of expectorated sputum or a specimen of respiratory secretions obtained by endotracheal aspiration in intubated subjects, or by bronchoscopy with bronchoalveolar lavage (BAL), mini BAL or protected specimen brush (PSB) sampling.

Additional Inclusion Criteria - cUTI Subjects

  1. Subject had a positive urine culture within the 5 days prior to study entry, containing ?10^5 colony-forming unit (CFU)/mL of at least 1 carbapenem non susceptible, MBL positive Gram negative bacteria, ie, the isolate from the study qualifying culture.
  2. Subject had pyuria in the 5 days prior to study entry as determined by a midstream clean catch or catheterized urine specimen with ?10 white blood cells (WBCs) per high power field on standard examination of urine sediment or ?10 WBCs/mm3 in unspun urine.
  3. Subject demonstrates either acute pyelonephritis or complicated lower UTI without pyelonephritis as defined by the following criteria:

    a. Acute pyelonephritis indicated by flank pain (which must have onset or worsened within 7 days of enrollment) or costovertebral angle tenderness on examination and at least 1 of the following: i) Fever, defined as body temperature ?38°C (with or without patient symptoms of rigor, chills, or warmth); ii) Nausea and/or vomiting. OR b. Complicated lower UTI, as indicated by qualifying symptoms plus at least 1 complicating factor as follows: i) Qualifying symptoms: subject must have at least 2 of the following symptoms with at least 1 symptom from Group A:

    ? Group A symptoms include dysuria, urgency, frequency, and or suprapubic pain;

    • Group B symptoms include fever (defined as body temperature ?38°C with or without patient symptoms of rigor, chills, warmth), nausea, and/or vomiting.

    ii) Complicating factors: subject must have at least 1 of the following complicating factors:

    ? Documented history of urinary retention (male subjects);

    ? Obstructive uropathy that is scheduled to be medically or surgically relieved during study therapy and before the EOT;

    • Functional or anatomical abnormality of the urogenital tract, including anatomic malformations or neurogenic bladder, or with a postvoid residual urine volume of at least 100 mL;
    • Use of intermittent bladder catheterization or presence of an indwelling bladder catheter for at least 48 hours;
    • Urogenital procedure (such as cystoscopy or urogenital surgery) within the 7 days.

    Additional Inclusion Criteria - BSI Subjects

  1. Subject has a confirmed diagnosis of primary BSI or catheter related BSI (CR- BSI).
  2. Consecutive positive duplicate blood cultures (n=2) within 5 days prior to study entry indicating presence of a carbapenem non- susceptible, MBL-producing Gram- negative bacteria. Subjects with polymicrobial blood infections may be included in the study.
  3. Signs and symptoms of systemic infection characterised by at least one of the following:

    a. Chills, rigors, or fever (temperature of ?38.0°C or ?100.4°F); b. Elevated white blood cell count (?10,000/mm3) or left shift (>15% immature polymorphonuclear leukocytes (PMNs)).

Exclusion Criteria All Subjects 1. Subject has an Acute Physiology and Chronic Health Evaluation (APACHE) II score >30.

2. Subjects unlikely to respond to up to 14 days of study treatment. 3. History of serious allergic reaction (anaphylaxis, angioedema, bronchospasm, hypersensitivity) to any systemic antibacterial allowed per protocol.

4. Subject has previously been treated with ATM-AVI Subject with known Clostridium difficile associated diarrhea. 5. Subjects with perinephric infection. 6. Colonization with an MBL-producing Gram-negative bacteria without signs or symptoms.

7. Estimated CrCL ?15 mL/min or anticipated requirement for dialysis during the study.

8. Hepatic disease as indicated by ALT or AST >3 x ULN at Screening. Exception: AST and/or ALT up to 5 x ULN if these elevations are acute and directly related to the infectious process.

9. Bilirubin >2 x ULN, unless related to the acute infection or due to known Gilbert's disease.

10. Alkaline phosphatase (ALP) >3 x ULN. Exception: up to <5 x ULN if this value is acute and related to the infectious process.

11. Absolute neutrophil count <500/mm3.

Additional Exclusion Criteria - cIAI Subjects

1. Subject has infections limited to the hollow viscous, such as simple cholecystitis, gangrenous cholecystitis without rupture, and simple appendicitis, or has acute suppurative cholangitis, infected necrotizing pancreatitis, or pancreatic abscess.

2. Subject has abdominal wall abscess or small bowel obstruction without perforation or ischemic bowel without perforation.

3. Subject has a cIAI managed by staged abdominal repair (STAR), or "open abdomen" technique, or marsupialization. This criterion is intended to exclude subjects in whom the abdomen is left open, particularly those for whom re operation is planned.

4. Subject who has prior liver, pancreas or small bowel transplant.

Additional Exclusion Criteria - HAP/VAP Subjects 1. APACHE II score <10. 2. Subjects with lung abscess, pleural empyema, or post obstructive pneumonia. 3. Subject is a recipient of a lung or heart transplant. 4. Subjects with myasthenia gravis.

Additional exclusion criteria - cUTI Subjects

  1. Subjects with suspected or confirmed complete obstruction of any portion of the urinary tract, perinephric or intrarenal abscess, or prostatitis, or history of any illness that, in the opinion of the investigator, may confound the results of the study or pose additional risk in administering the study therapy to the subject.
  2. Subjects with renal transplantation.
  3. Subjects with a permanent urinary diversion (eg, with ileal loops, cutaneous ureterostomy or vesicoureteral reflux).
  4. Subjects who are likely to receive ongoing antibacterial drug prophylaxis after treatment of cUTI (eg, subjects with vesico-ureteric reflux).
  5. Any recent history of trauma to the pelvis or urinary tract.
  6. Subjects with uncomplicated urinary tract infections (generally female subjects with urinary frequency, urgency, or pain or discomfort without systemic symptoms or signs of infection).

Additional exclusion criteria - BSI Subjects

1. Subject has a prosthetic cardiac valve or synthetic endovascular graft. 2. Subject has a suspected or documented medical condition with well-defined requirement for prolonged antibiotic treatment (eg, infectious endocarditis, osteomyelitis/septic arthritis, undrainable/undrained abscess, unremoveable/unremoved prosthetic associated infection).

Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Not Provided
 
 
NCT03580044
C3601009
2017-004544-38 ( EudraCT Number )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Yes
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
URL: http://
Pfizer
Pfizer
Allergan
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now